Redoxis AB

Redoxis AB is an SME in Lund, Sweden that has taken part in 6 EU-funded projects since 2008, receiving €1.6M in EU funding.

EU funding received€1.6M
EU projects6
As coordinator0
Running now0
First EU project2008
Latest project2020
CountrySweden
EU registration (PIC)998868074
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Redoxis AB's own share of each project, not the project's full budget.

  • FP7 (2007 to 2013)€922k · 3 projects
  • Horizon 2020€677k · 3 projects

Projects

6 EU-funded projects, newest first. Each links to the official record.

  • NeutroCurePartner

    Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.

    Horizon 2020 · 2020–2025 · Project on CORDIS ↗

    €400ktheir share
  • COSMICPartner

    COmbatting disorders of adaptive immunity with Systems MedICine

    Horizon 2020 · 2018–2022 · Project on CORDIS ↗

    €264ktheir share
  • REDOXITPartner

    Reactive oxygen species (ROS) as Elixirs against chronic Disease: OXidative regulatory mechanisms In T cells and neutrophils.

    Horizon 2020 · 2015–2019 · Project on CORDIS ↗

    €14ktheir share
  • NEURINOXPartner

    NOX enzymes as mediators of inflammation-triggered neurodegeneration: modulating NOX enzymes as novel therapies

    FP7 (2007 to 2013) · 2012–2016 · Project on CORDIS ↗

    €771ktheir share
  • BTCUREPartner

    BeTheCuRE

    FP7 (2007 to 2013) · 2011–2017 · Project on CORDIS ↗

    €1ktheir share
  • MASTERSWITCHPartner

    Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices

    FP7 (2007 to 2013) · 2008–2013 · Project on CORDIS ↗

    €150ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • alkaline earth metals
  • amyotrophic lateral sclerosis
  • autoimmune diseases
  • drug discovery
  • enzymes
  • immunology
  • inflammatory diseases
  • multiple sclerosis
  • oncology
  • proteomics
  • rheumatology

Redoxis AB is listed on EUACC

See the startup profile for its product, team and what it is looking for.

Open the startup profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime